Groundbreaking AI models generate novel antibiotics NG1 and DN1 that effectively combat multidrug-resistant superbugs like gonorrhea and MRSA, iteratively building and optimizing molecular structures for potency and safety.
Oracle unveils MCP server enabling AI agents to autonomously query and reason over enterprise data in Oracle Databases, boosting productivity and data utilization across sectors like pharma, healthcare, and finance.
AI startup Isomorphic Labs, spun out of DeepMind, prepares for human trials of drugs designed by cutting-edge AI paired with pharma experts, aiming for 100% conviction drugs will work before trials, promising faster, cheaper and more accurate medicine design.
A new AI test can identify which men with high-risk prostate cancer will benefit most from the life-extending drug abiraterone, potentially saving lives and NHS costs by avoiding unnecessary treatment for those unlikely to benefit.
AI's ability to rapidly analyze massive datasets is revolutionizing drug discovery, cutting research timelines from around 6 years to as little as 2-4 years, leading to significant cost savings and faster delivery of life-saving treatments, as evidenced by the accelerated development of COVID-19 mRNA vaccines.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
Researchers developed a multimodal AI tool that combines language models and graph-based models to efficiently design new molecules with desired properties from natural language queries, outperforming existing methods and potentially automating the entire molecule design and synthesis process.
Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.